68Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with 99mTc-ASC lymphoscintigraphy: a prospective study

Guozhu Hou1,2, Yuanyuan Jiang1,2, Wenshuai Xu3, Zhaohui Zhu1,2, Li Huo1,2, Xiaoyuan Chen4*, Fang Li1,2,6*, Kai-Feng Xu3,6* and Wuying Cheng1,2,5*

Abstract

Background: Lymphangioleiomyomatosis (LAM) is a rare multisystem disease characterized by cystic lung disease and extrapulmonary manifestations, including lymphatic system disorder. The objective of this study was to investigate the findings of 68Ga-NOTA-Evans Blue (NEB) PET/CT in LAM and compare it with that of 99mTc-ASC lymphoscintigraphy.

Methods: Ten patients diagnosed with LAM according to the American Thoracic Society/Japanese Respiratory Society guidelines for LAM were recruited in this study. PET/CT acquisition was performed at 20 to 40 min after subcutaneous injection of 68Ga-NEB into the first interdigital spaces of both feet (0.3 ml, 37 MBq/foot). All subjects also underwent 99mTc-antimony sulfide colloid (ASC) lymphoscintigraphy within a week for comparison.

Results: 68Ga-NEB PET/CT displayed various lymphatic system abnormalities in 10 (100%) of 10 patients. These included pulmonary lymphatic abnormalities in 10 (100%) of 10 patients, enlarged lymph nodes in 5 (50%), lymphangioleiomyomas in 2 (20%), dilation of the lumbar trunk and/or iliac lymph vessels in 5 (50%), thoracic duct dilation in 2 (20%), chylous effusion in 1 (10%). For pulmonary lymphatic abnormalities, the positive rates of 68Ga-NEB PET/CT and 99mTc-ASC lymphoscintigraphy were 100% (10/10) and 10% (1/10), respectively (P < 0.001). As for the 7 patients with extrapulmonary lymphatic manifestations, 68Ga-NEB PET/CT also presented more information than 99mTc-ASC lymphoscintigraphy.
Introduction

Lymphangioleiomyomatosis (LAM), a rare multi-system disease primarily found in women, is characterized by diffuse cystic changes in the lung [1, 2]. LAM mainly affects the lung, but can also involve the thoracic and abdominal axial lymphatics, including the lymph nodes in the pelvic cavity, retroperitoneum, mediastinum, and thoracic duct [3]. LAM lesions are generated by the proliferation of immature smooth muscle-like cells (LAM cells) [4]. Patients with LAM may present with dyspnea, chylous pleural effusion, pneumothorax, hemoptysis, and symptoms associated with extrapulmonary involvement [5]. Extrapulmonary manifestations, occurring in more than 70% of patients, include angiomyolipomas (AMLs), lymphangioleiomyomas, lymphadenopathy, and lymphatic dilation [6].

A previous retrospective study used CT lymphangiography to evaluate the lymphatic system disorder in 27 patients with LAM and observed various axial lymphatic system manifestations in the thorax and abdomen [7]. However, nuclear medicine imaging findings of the lymphatic system disorder in LAM patients have not been described comprehensively before. 99mTc-antimony sulfide colloid (ASC) lymphoscintigraphy is a widely used method for lymphatic mapping. Until now, there has been no report of 99mTc-ASC lymphoscintigraphy findings of LAM. 68Ga-NOTA Evans Blue (68Ga-NEB) is an albumin-binding PET radiotracer for lymphatic imaging and has been used in several lymphatic disorders for diagnosis and evaluation [8–14]. We recently reported a LAM patient whose 68Ga-NEB PET/CT not only clearly displayed the lymphatic disorders in the abdomen but also unexpectedly revealed diffuse abnormal NEB activity in bilateral lungs, suggesting the existence of pulmonary lymphatic circulation abnormality [15]. Therefore, in this current prospective study, we aimed to further evaluate 68Ga-NEB PET/CT in LAM and to compare it with 99mTc-ASC lymphoscintigraphy.

Patients and methods

Patients

This study was part of the study “Application of 68Ga-NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders” registered at clinicaltrials.gov (NCT 02496013) and approved by the Institute Review Board of Peking Union Medical College Hospital (PUMCH) (IRB protocol #ZS-2131).

A total of 10 patients (10 women, aged 21–50 years [37.40 ± 10.10 years]) diagnosed with LAM according to the American Thoracic Society/Japanese Respiratory Society guidelines [16] for LAM were consecutively recruited from October 2019 to May 2020. All patients were recommended by the Department of Pulmonary and Critical Care Medicine. The exclusion criteria were patients (1) with mental illness; (2) with severe liver or kidney dysfunction; (3) with hematopoietic dysfunction; (4) who were pregnant or breast-feeding. All patients underwent both 68Ga-NEB PET/CT and 99mTc-ASC scintigraphy within 1 week. Statement of informed consent was obtained from all patients included in the study.

68Ga-NEB PET/CT study

The 68Ga-NEB was produced following our previously published procedure [9]. 68Ga-NEB was subcutaneously injected into the first interdigital spaces of both feet (0.3 mL, 37 MBq/foot). The patients were requested to walk after tracer injection. 20–40 min later, PET scan (7–10 bed positions, 2 min/bed) covering from the feet to the neck was acquired after a low-dose CT scan (120 keV; 100 mAs; 1.3 pitch; 2.5 mm slice thickness; 0.5 s rotation time; estimated radiation dose 9.0 mGy). The acquired images were reconstructed using the ordered subsets expectation–maximization (OSEM) algorithm (2 iterations, 10 subsets, Gaussian filter, 192 × 192 matrix).

99mTc-ASC lymphoscintigraphy

All patients underwent 99mTc-ASC lymphoscintigraphy for comparison within a week of 68Ga-NEB PET/CT. The lymphoscintigraphy acquisition was performed at 1 h after 99mTc-ASC was subcutaneously injected into first and second interdigital spaces of both feet (0.5 mL, 37 MBq/foot). Images were acquired with a double-head gamma camera and a low-energy high-resolution parallel whole collimator in whole-body scanning mode with a 256 × 1024 matrix at a scan speed of 15 cm/min.

Image interpretation and statistical analysis

Visual analysis was applied for image interpretation. The images were read by two experienced nuclear medicine physicians. The criteria of the visual analysis were as

Conclusion: 68Ga-NEB PET/CT visualized pulmonary lymphatic abnormality and displayed extrapulmonary lymphatic system disorders of LAM, and might play a role in the diagnosis and evaluation of the disease. 68Ga-NEB PET/CT is advantageous over conventional 99mTc-ASC lymphoscintigraphy in LAM by providing more detailed information of lymphatic dysfunction.

Keywords: Lymphangioleiomyomatosis, 68Ga-NOTA-Evans Blue (68Ga-NEB), PET/CT, Lymphoscintigraphy
follows: (1) visualization of pulmonary lymphatic abnormality (yes/no) and the distribution of tracer uptake; (2) dilated lymphatic vessels (yes/no) and sites; (3) the presence and locations of lymphadenopathy; (4) lymphangioleiomyomas (yes/no) and distribution of tracer; (5) chylous effusion (yes/no). Data were expressed as mean±SD. Statistical analyses were done with the SPSS Statistics software (version 24.0, IBM SPSS Inc.). The Chi-squared test was used to compare the positive rates of 68Ga-NEB PET/CT and 99mTc-ASC lymphoscintigraphy. The P-value<0.05 was considered statistically significant.

Results
68Ga-NEB PET/CT findings
68Ga-NEB PET/CT displayed various abnormal lymphatic system manifestations in all 10 patients (100%) with LAM. Abnormally increased NEB activity in the lung was observed in 10 of 10 (100%) patients. The NEB activity was diffusely distributed in bilateral lungs (Fig. 1, patient #2).

Seven (70%) of 10 patients were presented with extrapulmonary lymphatic manifestations on 68Ga-NEB PET/CT. Multiple enlarged lymph nodes were found in 5 (50%) of 10 patients with intense NEB activity on PET/CT images. The sizes ranged from 1.0 to 1.9 cm. These nodes were retroperitoneal and pelvic in 2 patients, and were retroperitoneal in 3 patients. 68Ga-NEB PET/CT showed retroperitoneal and pelvic lymphangioleiomyomas in 2 (20%) patients, which were presented as hypoattenuating partially cystic and partially solid mass, measuring 23.9 cm and 4.2 cm at maximum diameter, respectively. NEB accumulation was observed in part of the cystic components (Fig. 2, patient #8). Dilation of the thoracic segment of the thoracic duct was noted in 2 patients (20%), measuring 1.4 and 1.6 cm in diameter, respectively. 5 patients (50%) had retroperitoneal lumbar trunk and/or iliac lymphatic vessel dilation, with sizes ranging from 0.5 to 3.5 cm. Abdominopelvic chylous
effusion was observed in one patient (10%), demonstrating mild NEB activity.

Comparison between $^{99m}$Tc-ASC lymphoscintigraphy and $^{68}$Ga-NEB PET/CT findings

Four (40%) of 10 patients showed positive findings on $^{99m}$Tc-ASC lymphoscintigraphy. For pulmonary lymphatic abnormality, $^{68}$Ga-NEB PET/CT was positive in all 10 patients (100%), while $^{99m}$Tc-ASC lymphoscintigraphy was only positive in 1 patient (10%, $P < 0.001$; Fig. 3, patient #7). For extrapulmonary lymphatic system abnormalities, the results of $^{99m}$Tc-ASC lymphoscintigraphy and $^{68}$Ga-NEB PET/CT were consistent in 1 patient (Patient #2), while $^{68}$Ga-NEB PET/CT revealed more lesions than $^{99m}$Tc-ASC lymphoscintigraphy in 6 patients. Compared to $^{99m}$Tc-ASC lymphoscintigraphy, $^{68}$Ga-NEB PET/CT showed added value in 9/10 patients for pulmonary lymphatic abnormalities, 5/10 patients for enlarged lymph nodes, 3/10 patients for dilation of the lumbar trunk and/or iliac lymph vessels, 1/10 patients for thoracic duct dilation and 1/10 patients for lymphangioleiomyomas. In patient #1 and #9, $^{99m}$Tc-ASC lymphoscintigraphy was unable to show the retroperitoneal lymph nodes, which were detected by $^{68}$Ga-NEB PET/CT. In patient #4, $^{68}$Ga-NEB PET/CT revealed multiple lymphatic abnormalities including retroperitoneal lymph nodes and lymphatic vessel dilation, thoracic duct dilation, and pelvic lymphangioleiomyoma while $^{99m}$Tc-ASC lymphoscintigraphy appeared normal. In patient #5 and #10, $^{68}$Ga-NEB PET/CT provided more information than $^{99m}$Tc-ASC lymphoscintigraphy by visualizing retroperitoneal lumbar trunk dilation and/or enlarged lymph nodes (Fig. 4, patient #5). Chyloperitoneum with mild tracer activity was found on both $^{68}$Ga-NEB PET/CT and $^{99m}$Tc-ASC lymphoscintigraphy in patient #8. $^{68}$Ga-NEB PET/CT showed multiple lymph nodes in the retroperitoneum and pelvis which $^{99m}$Tc-ASC lymphoscintigraphy was unable to visualize (Table 1).

Extralymphatic system abnormality

Multiple round thin-walled air-filled cysts in the lung characteristic of LAM have been observed in all 10 patients on $^{68}$Ga-NEB PET/CT. 1 (10%) of 10 patients presented with 2 renal AMLs, with a size of 0.6 and 1.2 cm, respectively.
Discussion
LAM is characterized by the proliferation of LAM cells in the affected organs. LAM cells can produce VEGF-D, a lymphangiogenic growth factor [17]. It is speculated that VEGF-D promotes the local aggregation of lymphatic endothelial cells, which then promotes the formation of lymphatics [18]. Extensive lymphatic vessels in both pulmonary and extrapulmonary LAM lesions have already been noted and described as cystic or slit-like spaces within the LAM foci in histopathologic studies [19–22]. Our finding of diffuse NEB activity in the lung on PET/CT images, suggesting the hyperplasia and dilation of pulmonary lymphatic vessels, supported the findings of these histopathologic studies. Obviously, $^{68}$Ga-NEB PET/CT is an ideal imaging method to visualize the existence of extensive lymphatic changes in the lung region.

The existence of pulmonary lymphatic abnormality in LAM is not fully acknowledged in the clinic, which is attributed to the fact that in clinical practice, the examination of lymphatic vessels in lung specimen is not routinely performed as the presence of lymphatic vessel within LAM foci is not required for the pathologic diagnosis of LAM [23]. According to the American Thoracic Society/Japanese Respiratory Society guidelines, a definite diagnosis of LAM can be made based on the presence of cystic changes on HRCT of the chest characteristic of LAM and any of the following confirmatory features: renal AML, chylous effusion, lymphangioleiomyoma, adenopathy, lymphatic vessels dilation, and either definite or probable tuberous sclerosis complex (TSC) [23]. If these extrapulmonary features of LAM are not evident, a lung biopsy would be required to confirm the diagnosis. Since we were able to visualize pulmonary lymphatic abnormality by $^{68}$Ga-NEB PET/CT, pulmonary lymphatic abnormality might be considered as one additional confirmatory feature of LAM to aid the diagnosis and evaluation of the disease. With $^{68}$Ga-NEB PET/CT, the confidence of diagnosis in patients, especially those found with only pulmonary cystic changes would be increased.

Extrapulmonary lymphatic system manifestations of LAM observed in our study included adenopathy, lymphatic vessel dilation, retroperitoneal and pelvic lymphangioleiomyoma, and chylous effusion. As mentioned above, these extrapulmonary lymphatic system disorders are confirmatory features of LAM, and the
demonstration of these abnormalities with \(^{68}\text{Ga-NEB}\) PET/CT may aid the diagnosis and evaluation of the disease. Lymph adenopathy and lymphatic vessel dilation, generally presented with intense NEB activity, could be easily visualized on PET/CT images.

We also noticed that in lymphangioleiomyoma, manifested as a well-circumscribed multilocular mass with central fluid rich region on CT scan, NEB accumulation was only seen in part of the cystic components. It was reported that lymphangioleiomyoma is a result of smooth muscle cell proliferation in the lymph vessels, which then causes dilatation and obstruction in the lymph vessels and collection of chylous material [20, 24–26]. Therefore, part of the cystic components may communicate with the lymphatic system, which leads to tracer accumulation.

The positive rate of \(^{68}\text{Ga-NEB}\) PET/CT in detecting pulmonary lymphatic disorder is significantly higher than that of \(^{99m}\text{Tc-ASC}\) lymphoscintigraphy ($P<0.001$). Considering that NEB binds to albumin during circulation and the size of NEB/albumin complex is much smaller than \(^{99m}\text{Tc-ASCs}\), it is thus easier for NEB to reach the involved pulmonary lymph vessels, which are generally very small in diameter [13, 14, 19]. A previous study reported that CT lymphangiography showed intrapulmonary lymphatic vessel dilation in 11% (3/27) LAM patients [7]. It is also worth noting that the size of the observed dilated intrapulmonary lymphatic vessels ranged from 0.1 to 0.4 cm, raising the possibility that CT lymphangiography is able to detect relatively large lymphatic vessels but not small ones, which might explain

---

**Fig. 4** A 30-year-old woman (patient #5) with LAM. The patient had ascites and laboratory examination indicated chyloperitoneum. \(^{99m}\text{Tc-ASC}\) lymphoscintigraphy (A, red arrows) showed mild diffuse activity in the abdomen with barely no chest activity. \(^{68}\text{Ga-NEB}\) PET/CT images revealed abnormal activity in the chest (B, MIP) and retroperitoneal lymphatic vessel dilation (white arrows) and lymphadenopathy (green arrows) (C, PET; D, CT; E, fusion). Interestingly, the abnormal activity in the ascites was not as obvious on \(^{68}\text{Ga-NEB}\) PET/CT images as on \(^{99m}\text{Tc-ASC}\) lymphoscintigraphy.
the low positive rate (11%) of CT lymphangiography. Further studies of comparing 68Ga-NEB PET/CT and CT lymphangiography in evaluating LAM in more patients are need to confirm this finding.

In this study, 68Ga-NEB PET/CT is also more revealing than 99mTc-ASC lymphoscintigraphy by presenting more extrapulmonary lymphatic disorders. Our results demonstrated that, compared to 99mTc-ASC lymphoscintigraphy, 68Ga-NEB PET/CT showed added value in 9/10 patients for the detection of pulmonary lymphatic abnormalities, 5/10 patients for enlarged lymph nodes, 3/10 patients for dilation of the lumbar trunk and/or iliac lymph vessels, 1/10 patients for thoracic duct dilation and 1/10 patients for thoracic duct dilation and lymphangioleiomyomas. Similarly, a previous report also showed that 68Ga-NEB PET/CT presented more clinically important information than did 99mTc-ASC lymphoscintigraphy in patients with lymphedema or chylous leakages [14]. This might be due to the fact that 99mTc-ASC lymphoscintigraphy has an intrinsic disadvantage compared with 68Ga-NEB PET/CT. PET has greater intrinsic sensitivity compared to SPECT, and 68Ga-NEB PET has better spatial resolution than 99mTc-ASC lymphoscintigraphy. In addition, 68Ga-NEB PET/CT images are dynamic 3-dimensional whereas traditional 99mTc-ASC lymphoscintigraphy acquires only static 2-dimensional images. 68Ga-NEB PET/CT is also advantageous over 99mTc-ASC lymphoscintigraphy in shorter waiting and acquisition time.

Lymphatic system abnormality has always been considered as complications of LAM and is reported to be found in about 20% of LAM patients [27, 28]. In our study, 70% (7/10) patients presented with extrapulmonary lymphatic manifestations on 68Ga-NEB PET/CT. However, the demonstration of the existence of pulmonary lymphatic changes with 68Ga-NEB PET/CT increases the proportion of cases with lymphatic involvement in our population to 100%. Based on this finding, we speculate that LAM patients who were diagnosed with only pulmonary cystic changes in the past might also have lymphatic involvement which conventional imaging methods failed to detect. Our finding of a high proportion of LAM cases with lymphatic involvement combined with the findings of histopathological studies suggest that lymphatic dysfunction may be a key mechanism in LAM pathogenesis [19–22]. Elucidation of the role of lymphatic dysfunction in LAM may have the potential to develop new therapies targeting lymphatic circulation to inhibit the progression of LAM [19]. Therefore, a great deal remains to be learned about lymphatic involvement in LAM, including its role in pathogenesis of the disease and its potential as a treatment target.

Several limitations of this study must be pointed out. First, the study is limited by the lack of histopathological correlation of 68Ga-NEB PET/CT findings of pulmonary lymphatic changes. The second limitation is the small sample size of 10 patients with LAM. In future studies, we will collect more patients with LAM to further investigate the role of 68Ga-NEB PET/CT in assessing severity degree, treatment response, and predicting the prognosis of the disease. Thirdly, 68Ga-NEB PET/CT is able to visualize the pulmonary lymphatic abnormality and may have the potential in separating LAM from other cystic lung diseases such as emphysema, Langerhans cell histiocytosis, Sjögren syndrome with cystic changes in lung, and

| Patient | Age/sex | Pulmonary lymphatic abnormalities | Enlarged lymph nodes | Dilation of lumbar trunk and/or iliac lymph vessels | Thoracic duct dilation | Lymphangioleiomyomas | Chylous effusion |
|---------|---------|----------------------------------|----------------------|-----------------------------------------------|-----------------------|----------------------|-----------------|
|         |         | NEB | ASC | NEB | ASC | NEB | ASC | NEB | ASC | NEB | ASC | NEB | ASC |
| 1       | 34/F    | Y   | N   | Y   | N   | N   | N   | N   | N   | N   | N   | N   |
| 2       | 50/F    | Y   | Y   | N   | N   | Y   | Y   | N   | N   | N   | N   | N   |
| 3       | 48/F    | Y   | N   | Y   | N   | Y   | Y   | N   | N   | N   | N   | N   |
| 4       | 33/F    | Y   | N   | Y   | N   | Y   | Y   | N   | N   | N   | N   | N   |
| 5       | 30/F    | Y   | N   | Y   | N   | Y   | Y   | N   | N   | N   | N   | N   |
| 6       | 29/F    | Y   | N   | N   | N   | N   | N   | N   | N   | N   | N   | N   |
| 7       | 34/F    | Y   | N   | N   | N   | N   | N   | N   | N   | N   | N   | N   |
| 8       | 48/F    | Y   | N   | Y   | N   | N   | N   | N   | Y   | Y   | N   | N   |
| 9       | 47/F    | Y   | N   | Y   | N   | Y   | Y   | Y   | N   | N   | N   | N   |
| 10      | 21/F    | Y   | N   | N   | N   | N   | N   | N   | N   | N   | N   | N   |

The bold (Y) indicate that the imaging results are positive. The “Y-N” pairs where NEB would be positive and ASC would be negative appear in italics. The "Y" of the "Y-N" pairs where NEB would be positive and ASC would be negative appear in bold italics.
Birt-Hogg-Dubé syndrome. However, the current study did not examine the findings of 68Ga-NEB PET in other cystic lung diseases. In the future, studies investigating the 68Ga-NEB PET/CT findings of other cystic lung diseases were required to confirm this. In addition, we did not make correlations between VEGF-D level and the degree of lymphatic abnormality with 68Ga-NEB PET/CT in this study because VEGF-D data is not available in every patient. Besides, the sample size of 10 patients is too small, making it difficult to grade the severity of lymphatic abnormality with 68Ga-NEB PET/CT. In the future, we will collect more patients to grade the severity of lymphatic abnormality with 68Ga-NEB PET/CT, and to correlate VEGF-D level with 68Ga-NEB PET/CT findings.

Conclusions
68Ga-NEB PET/CT demonstrated pulmonary lymphatic abnormality and displayed various extrapulmonary lymphatic system disorders of LAM, making it a promising method in the diagnosis and evaluation of the disease. The presence of pulmonary lymphatic abnormality, if added in the confirmatory features of LAM, may aid in the diagnosis of the disease. Compared with 99mTc-ASC lymphoscintigraphy, 68Ga-NEB PET/CT is a more accurate method in evaluating LAM by providing more information.

Abbreviations
LAM: Lymphangioleiomyomatosis; NEB: NOTA-Evans Blue; ASC: Antimony sulfide colloid; TSC: Tuberous sclerosis complex; AMLs: Angiomyolipomas; PET/CT: Positron emission tomography/computed tomography; SPECT/CT: Single photon emission computed tomography/computed tomography.

Acknowledgements
We thank all the patients and families for their contribution to this work.

Authors’ contributions
GH: data collecting; data analysis and manuscript writing. WX: data collecting, data analysis, and manuscript writing. XC: study design. K-FX: study design. XC: study design. WC: study design. The authors read and approved the final manuscript.

Funding
This report was funded in part by the National Natural Sciences Foundation of China (no.81371588), the National Key Research and Development Program of China (2016YFC0901502, 2016YFC0901500, U20A20341), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) (2017-12M-2-001). Start-up fund from the National University of Singapore. None declared to all authors.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author.

Declarations
Ethics approval and consent to participate
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional review board of PUMCH (IRB protocol #25-2131). This study was registered at clinicaltrials.gov (NCT 04273334). Statement of informed consent was obtained from all individual participants included in the study.

Consent for publication
Consent for publication was obtained from all participants.

Competing interests
No competing interests were declared.

Author details
1Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. 2Department of Respiratory Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. 3Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. 4Departments of Diagnostic Radiology, Chemical and Biomolecular Engineering, and Biomedical Engineering, National University of Singapore, Singapore 117545, Singapore. 5Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. 6Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Received: 21 January 2021 Accepted: 29 May 2021
Published online: 16 June 2021

References
1. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. New Engl J Med. 1990;323(18):1254–60.
2. Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151(2 Pt 1):527–33.
3. Chu SC, Horiba K, Usuki J, Avila NA, Chen CC, Travis WD, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest. 1999;115(4):1041–52.
4. Matsui K, Beasley MB, Nelson WK, Barnes PM, Bechtle J, Falk R, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25(4):479–84.
5. Hayashida M, Seyama K, Inoue Y, Fujimoto K, Kudo K. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology. 2007;12(4):525–30.
6. Aberle DR, Hansell DM, Brown K, Tashkin DP. Lymphangioleiomyomatosis: CT, chest radiographic, and functional correlations. Radiology. 1990;176(2):381–7.
7. Zhang C, Chen X, Wen T, Zhang Q, Huo M, Dong J, et al. Computed tomography lymphangiography findings in 27 cases of lymphangioleiomyomatosis. Acta Radiol (Stockholm, Sweden: 1987). 2017;58(11):1342–8.
8. Hou G, Hou B, Jiang Y, Zhi Z, Long X, Chen X, et al. 68Ga-NOTA-Evans Blue TOF PET/MR Lymphoscintigraphy Evaluation of the Severity of Lower Limb Lymphedema. Clin Nucl Med. 2019;44(6):439–45.
9. Zhang J, Lang L, Zhi Z, Li F, Niu G, Chen X. Clinical translation of an albumin-binding PET radiotracer 68Ga-NEB. J Nucl Med. Off Publ Soc Nucl Med. 2015;56(10):1609–14.
10. Hou G, Jiang Y, Jian S, Niu Y, Cheng W. Hemolymphangioma involving bones and bladder detected on 68Ga-NEB PET/CT: a rare case report. Medicine. 2019;98(15):e15213.
11. Hou G, Li X, Hou B, Zhou W, Cheng W. Lymphangioma on 68Ga-NOTA-Evans Blue PET/MR. Clin Nucl Med. 2018;43(7):553–5.
12. Niu G, Chen X. Lymphatic imaging: focus on imaging probes. Theranostics. 2015;5(7):866–97.
13. Long X, Zhang J, Zhang D, o-C, Chi C, Yang E, et al. Microsurgery guided by sequential preoperative lymphography using 68Ga-NEB PET and MRI in patients with lower-limb lymphedema. Eur J Nucl Med Mol Imaging. 2017;44(9):1501–10.
14. Zhang W, Wu P, Li F, Tong G, Chen X, Zhu Z. Potential applications of using 68Ga-Evans Blue PET/CT in the evaluation of lymphatic disorder: preliminary observations. Clin Nucl Med. 2016;41(4):302–8.
15. Hou G, Xu W, Jiang Y, Xu KF, Chen X, Li F, et al. Lymphangiomyomatosis revealed by 68Ga-NOTA-Evans Blue PET/CT. Eur J Nucl Med Mol Imaging. 2020;47(10):2469–70.
16. Gupta N. Lymphangiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. Off Am Thoracic Soc/Jpn Respir Soc Clin Pract Guidel. 2017;196(10):1337–48.
17. Seyama K,Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangiomyomatosis. Lymphat Res Biol. 2006;4(3):143–52.
18. Henske EP, McCormack FX. Lymphangiomyomatosis - a wolf in sheep's clothing. J Clin Invest. 2012;122(11):3807–16.
19. Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, et al. Lymphangiogenesis in lymphangiomyomatosis: its implication in the progression of lymphangiomyomatosis. Am J Surg Pathol. 2004;28(8):1007–16.
20. Carrington CB, Cugell DW, Gaensler EA, Marks A, Redding RA, Schaaf JT, et al. Lymphangiomyomatosis: Physiologic-pathologic-radiologic correlations. Am Rev Respir Dis. 1977;116(6):977–95.
21. Vázquez JJ, Fernández-Cuervo L, Fidalgo B. Lymphangiomyomatosis: morphogenetic study and ultrastructural confirmation of the histogenesis of the lung lesion. Cancer. 1976;37(5):2321–8.
22. Basset F, Soler P, Marsac J, Corrin B. Pulmonary lymphangiomyomatosis: three new cases studied with electron microscopy. Cancer. 1976;38(6):2357–66.
23. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangiomyomatosis. Eur Respir J. 2010;35(1):14–26.
24. Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangiomyomatosis: abdominopelvic CT and US findings. Radiology. 2000;216(1):147–53.
25. Cornog JL Jr, Enterline HT. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopercytoma. Cancer. 1966;19(12):1909–30.
26. Joliat G, Stalder H, Kapanci Y. Lymphangiomyomatosis: a clinic-anatomical entity. Cancer. 1973;31(2):455–61.
27. Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, et al. The NHLBI lymphangiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173(1):105–11.
28. Zhan Y, Shen L, Xu W, Wu X, Zhang W, Wang J, et al. Functional improvements in patients with lymphangiomyomatosis after sirolimus: an observational study. Orphanet J Rare Dis. 2018;13(1):34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.